$ITOS
Iteos Therapeutics Inc

2024 Q1 Form 10-K Financial Statement

#000095017024026866 Filed on March 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $12.60M
YoY Change -100.0% -100.0% -95.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.70M $12.37M $50.40M
YoY Change 6.51% 11.42% 14.67%
% of Gross Profit
Research & Development $34.53M $27.78M $113.3M
YoY Change 34.89% 9.27% 16.37%
% of Gross Profit
Depreciation & Amortization $304.0K $227.0K $898.0K
YoY Change 36.94% 1.79% 11.83%
% of Gross Profit
Operating Expenses $47.23M $40.15M $163.7M
YoY Change 25.87% 9.92% 15.85%
Operating Profit -$47.23M -$151.1M
YoY Change 89.46% -219.61%
Interest Expense $7.386M $7.842M $31.77M
YoY Change -5.92% -30.97% 179.68%
% of Operating Profit
Other Income/Expense, Net $2.093M $4.116M $4.083M
YoY Change 26.93% -168.62% -47.57%
Pretax Income -$36.00M -$28.19M -$109.0M
YoY Change 150.85% -223.93% -173.3%
Income Tax $2.214M $2.363M $3.612M
% Of Pretax Income
Net Earnings -$38.20M -$30.55M -$112.6M
YoY Change 144.87% -249.37% -216.44%
Net Earnings / Revenue -894.01%
Basic Earnings Per Share -$1.07 -$3.15
Diluted Earnings Per Share -$1.07 -$0.85 -$3.15
COMMON SHARES
Basic Shares Outstanding 35.84M 35.78M 35.76M
Diluted Shares Outstanding 35.84M 35.76M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $449.1M $531.9M $531.9M
YoY Change -25.41% -13.25% -13.25%
Cash & Equivalents $146.6M $251.2M $251.2M
Short-Term Investments $302.5M $280.7M $280.7M
Other Short-Term Assets $25.32M $12.24M $12.24M
YoY Change 101.03% -3.66% -3.66%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $480.4M $550.7M $550.7M
YoY Change -21.94% -12.36% -12.36%
LONG-TERM ASSETS
Property, Plant & Equipment $5.264M $4.696M $10.73M
YoY Change 148.42% 121.4% 58.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $132.6M $100.5M $100.5M
YoY Change 26.9% -14.96% -14.96%
Other Assets $842.0K $883.0K $1.157M
YoY Change 155.93% 165.96% 104.06%
Total Long-Term Assets $149.4M $116.9M $116.9M
YoY Change 32.26% -7.7% -7.7%
TOTAL ASSETS
Total Short-Term Assets $480.4M $550.7M $550.7M
Total Long-Term Assets $149.4M $116.9M $116.9M
Total Assets $629.8M $667.6M $667.6M
YoY Change -13.53% -11.58% -11.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.530M $11.29M $11.29M
YoY Change -2.88% 47.39% 47.39%
Accrued Expenses $16.66M $7.058M $16.87M
YoY Change -6.02% -64.22% -17.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.56M $40.01M $40.01M
YoY Change 34.9% -4.73% -4.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $53.01M $52.35M $52.35M
YoY Change 6.61% 5.41%
Total Long-Term Liabilities $53.01M $52.35M $52.35M
YoY Change 6.61% 5.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.56M $40.01M $40.01M
Total Long-Term Liabilities $53.01M $52.35M $52.35M
Total Liabilities $88.57M $92.36M $92.36M
YoY Change 16.41% 0.76% 0.76%
SHAREHOLDERS EQUITY
Retained Earnings $86.40M $124.6M
YoY Change -61.03% -47.49%
Common Stock $36.00K $36.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $541.2M $575.2M $575.2M
YoY Change
Total Liabilities & Shareholders Equity $629.8M $667.6M $667.6M
YoY Change -13.53% -11.58% -11.58%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$38.20M -$30.55M -$112.6M
YoY Change 144.87% -249.37% -216.44%
Depreciation, Depletion And Amortization $304.0K $227.0K $898.0K
YoY Change 36.94% 1.79% 11.83%
Cash From Operating Activities -$32.40M -$13.77M -$103.8M
YoY Change 22.01% -49.34% -6.69%
INVESTING ACTIVITIES
Capital Expenditures $945.0K $1.412M $2.966M
YoY Change 694.12% 1117.24% 216.2%
Acquisitions
YoY Change
Other Investing Activities -$68.66M $62.97M $75.72M
YoY Change 117.43% -114.15% -117.02%
Cash From Investing Activities -$69.60M $61.56M $72.66M
YoY Change 119.6% -113.83% -116.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.113M
YoY Change 20.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.00K 307.0K 1.113M
YoY Change -96.19% -77.66% -43.9%
NET CHANGE
Cash From Operating Activities -32.40M -13.77M -103.8M
Cash From Investing Activities -69.60M 61.56M 72.66M
Cash From Financing Activities 22.00K 307.0K 1.113M
Net Change In Cash -104.5M 48.10M -33.59M
YoY Change 75.86% -110.21% -94.04%
FREE CASH FLOW
Cash From Operating Activities -$32.40M -$13.77M -$103.8M
Capital Expenditures $945.0K $1.412M $2.966M
Free Cash Flow -$33.35M -$15.18M -$106.7M
YoY Change 25.01% -44.38% -4.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001808865
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39401
CY2023 dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023 dei City Area Code
CityAreaCode
339
CY2023 dei Local Phone Number
LocalPhoneNumber
217 0162
CY2023 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
ITOS
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Public Float
EntityPublicFloat
380400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35843131
CY2023 dei Auditor Firm
AuditorFirmId
1133
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 itos Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q4 itos Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023 dei Auditor Name
AuditorName
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL
CY2023 dei Auditor Location
AuditorLocation
Zaventem, Belgium
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251177000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284803000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
281035000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
281035000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
280739000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
328359000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1001000
CY2023Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
135000
CY2022Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
0
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
6365000
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
1434000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12236000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12701000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
550652000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
628298000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
100208000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
100208000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
100539000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
118225000
CY2023Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
4508000
CY2022Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
1128000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
274000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
235000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6036000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4652000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
883000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2023Q4 us-gaap Assets
Assets
667588000
CY2022Q4 us-gaap Assets
Assets
754991000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11293000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7662000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7058000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14092000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8562000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5635000
CY2023Q4 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
9787000
CY2022Q4 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
0
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2063000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1180000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
12595000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1251000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
836000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40014000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42000000
CY2023Q4 itos Grants Repayable
GrantsRepayable
6609000
CY2022Q4 itos Grants Repayable
GrantsRepayable
6622000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4807000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3837000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40930000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2023Q4 us-gaap Liabilities
Liabilities
92360000
CY2022Q4 us-gaap Liabilities
Liabilities
91659000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35838080
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35838080
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35611219
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35611219
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
463799000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
435665000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13240000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9644000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
124633000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
237275000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
667588000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
754991000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12595000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
267630000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
344775000
CY2023 us-gaap Revenues
Revenues
12595000
CY2022 us-gaap Revenues
Revenues
267630000
CY2021 us-gaap Revenues
Revenues
344775000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113300000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97359000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59369000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50396000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43947000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40505000
CY2023 us-gaap Operating Expenses
OperatingExpenses
163696000
CY2022 us-gaap Operating Expenses
OperatingExpenses
141306000
CY2021 us-gaap Operating Expenses
OperatingExpenses
99874000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-151101000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
126324000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
244901000
CY2023 itos Grant Income
GrantIncome
2687000
CY2022 itos Grant Income
GrantIncome
2091000
CY2021 itos Grant Income
GrantIncome
10181000
CY2023 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
3527000
CY2022 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
1172000
CY2021 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
0
CY2023 us-gaap Interest Income Other
InterestIncomeOther
31774000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
11361000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
78000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4083000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7788000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1304000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109030000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148736000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3612000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52084000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-112642000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-112642000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
96652000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
214521000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.1
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.15
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.56
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35763520
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35552025
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35763520
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37766507
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-112642000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3631000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8478000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1635000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
35000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-148000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116238000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1635000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
88026000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
212886000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13794000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2943000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21561000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
925000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-8478000
CY2022 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-148000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27021000
CY2023 itos Stock Issued During Period Value Employee Stock Purchase Plan And Release Of Restricted Stock Units1
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndReleaseOfRestrictedStockUnits1
1113000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-3631000
CY2023 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
35000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-112642000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
CY2023 us-gaap Profit Loss
ProfitLoss
-112642000
CY2022 us-gaap Profit Loss
ProfitLoss
96652000
CY2021 us-gaap Profit Loss
ProfitLoss
214521000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
898000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
803000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
603000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
27021000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
21561000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
13794000
CY2023 itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-10234000
CY2022 itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-1728000
CY2021 itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
0
CY2023 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
0
CY2022 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
10000
CY2021 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
12000
CY2023 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
1015000
CY2022 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
2751000
CY2021 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4071000
CY2023 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
3400000
CY2022 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-1237000
CY2021 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-727000
CY2023 itos Refundable Income Taxes
RefundableIncomeTaxes
-4934000
CY2022 itos Refundable Income Taxes
RefundableIncomeTaxes
6107000
CY2021 itos Refundable Income Taxes
RefundableIncomeTaxes
-7544000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-184000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-590000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11789000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3036000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2761000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2280000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5342000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3096000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251451000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9959000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
823000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
397000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3480000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12595000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-267630000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
281128000
CY2023 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-1730000
CY2022 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-22200000
CY2021 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-17000000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103756000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111193000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
513140000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
290541000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
445004000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
366264000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2966000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
938000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1181000
CY2023 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
99000
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
120000
CY2021 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
61000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72658000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-446062000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1242000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1113000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
925000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2943000
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
1059000
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
716000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1113000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1984000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3659000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3602000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8526000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3176000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33587000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-563797000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
512381000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285038000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
446735000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285038000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2023 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
354000
CY2022 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
94000
CY2021 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
175000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2155000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5877000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
35000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
148000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
0
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6816000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22816000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32019000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96700000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
237300000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-112600000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
124600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, as well as the related disclosures of contingent assets and liabilities. The Company bases its estimates and assumptions on historical experiences, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ materially from these estimates.</span></p>
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
360000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
325000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2022Q4 itos Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q4 itos Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q4 itos Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 and 2022, the Company’s cash and cash equivalents consisted primarily of cash balances held in U.S. dollars in money market funds and money market accounts and euro in accounts with European banks in excess of publicly insured limits. The Company does not believe it is subject to unusual credit risk associated with commercial banking relationships.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company's fixed income securities consisted of investment grade U.S. treasury, U.S. government agency, and corporate securities. There are no securities in the Company's portfolio with a credit rating below "A-1".</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the Company's fixed income holdings as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> consisted of U.S. treasury and U.S. government agency securities. The Company does not believe it is subject to unusual credit risk associated with its investment portfolio.</span></p>
CY2023 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.205
CY2022 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2021 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
106000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
257000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
446584000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
281035000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
280739000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
100208000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
100539000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
328405000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
328359000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
118330000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
118225000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
446735000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
446584000
CY2023 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10200000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1800000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9078000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5578000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4382000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3457000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2023Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
6956000
CY2022Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
13496000
CY2023Q4 itos Accrued Professional Fees And Other Accrued Liabilities Current
AccruedProfessionalFeesAndOtherAccruedLiabilitiesCurrent
102000
CY2022Q4 itos Accrued Professional Fees And Other Accrued Liabilities Current
AccruedProfessionalFeesAndOtherAccruedLiabilitiesCurrent
596000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7058000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14092000
CY2023 itos Upfront Payment Received
UpfrontPaymentReceived
625000000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12595000
CY2022 itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-12595000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023 us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
7600000
CY2023 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
4419000
CY2022 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
6261000
CY2021 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
3167000
CY2023 itos Grant Income
GrantIncome
2687000
CY2022 itos Grant Income
GrantIncome
2091000
CY2021 itos Grant Income
GrantIncome
10181000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1001000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2023Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6813000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6977000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6401987
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.5
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2324597
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.25
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
184937
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.92
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
271427
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.14
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8270220
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.73
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16299000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8270220
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.73
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
16299000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4746431
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.01
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14859000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27021000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21561000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13794000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27000000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.6
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.94
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.46
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2200000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
28100000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
20400000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10700000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.334
CY2023 us-gaap Effective Income Tax Rate Reconciliation Gilti Percent
EffectiveIncomeTaxRateReconciliationGiltiPercent
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Gilti Percent
EffectiveIncomeTaxRateReconciliationGiltiPercent
0.189
CY2021 us-gaap Effective Income Tax Rate Reconciliation Gilti Percent
EffectiveIncomeTaxRateReconciliationGiltiPercent
0.152
CY2023 itos Effective Income Tax Rate Unrecognized Tax Benefits
EffectiveIncomeTaxRateUnrecognizedTaxBenefits
-0.016
CY2022 itos Effective Income Tax Rate Unrecognized Tax Benefits
EffectiveIncomeTaxRateUnrecognizedTaxBenefits
0.149
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-70172000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-72940000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47242000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-38858000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
221676000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
303706000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109030000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148736000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.033
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
0.049
CY2022 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
-0.022
CY2021 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
-0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.052
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.047
CY2023 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
-0.001
CY2022 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.001
CY2021 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.011
CY2023 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
-0.256
CY2022 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
0.135
CY2021 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
-0.014
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.033
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
3612000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
50750000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
41535000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1334000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
408000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3612000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52084000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21796000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13359000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
17980000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
12355000
CY2023Q4 itos Section174 Capitalized Research And Development Expenses
Section174CapitalizedResearchAndDevelopmentExpenses
27913000
CY2022Q4 itos Section174 Capitalized Research And Development Expenses
Section174CapitalizedResearchAndDevelopmentExpenses
14856000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5002000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3860000
CY2023Q4 itos Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1539000
CY2022Q4 itos Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1201000
CY2023Q4 itos Deferred Tax Aseets Accrued Vacation And Bonus
DeferredTaxAseetsAccruedVacationAndBonus
846000
CY2022Q4 itos Deferred Tax Aseets Accrued Vacation And Bonus
DeferredTaxAseetsAccruedVacationAndBonus
552000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1164000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
932000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
76240000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47115000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74398000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45421000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1842000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1694000
CY2023Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
1534000
CY2022Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
1196000
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
243000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
394000
CY2023Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
65000
CY2022Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
104000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1842000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1694000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
29000000
CY2020 itos Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income
NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome
0.80
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8500000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40900000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2023Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
1700000
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
2200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1730000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40930000
CY2023Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
CY2023 us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2023 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1200000
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0475
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-112642000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2155000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1201000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1500000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1468000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1435000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
941000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
764000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
590000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6698000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
640000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6058000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1251000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4807000
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
675000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
398000
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
254000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
96652000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
214521000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35763520
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35552025
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2214482
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2593407
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35763520
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37766507
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.1
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.15
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.56
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68
CY2023Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
1692558

Files In Submission

Name View Source Status
0000950170-24-026866-index-headers.html Edgar Link pending
0000950170-24-026866-index.html Edgar Link pending
0000950170-24-026866.txt Edgar Link pending
0000950170-24-026866-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img164189564_0.jpg Edgar Link pending
img164189564_1.jpg Edgar Link pending
img164189564_2.jpg Edgar Link pending
img164189564_3.jpg Edgar Link pending
img164189564_4.jpg Edgar Link pending
itos-20231231.htm Edgar Link pending
itos-20231231.xsd Edgar Link pending
itos-ex21_1.htm Edgar Link pending
itos-ex23_1.htm Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
itos-ex32_2.htm Edgar Link pending
itos-ex97_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
itos-20231231_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable